GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot2

Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

Example EvidenceVariable: GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis

Generated Narrative: EvidenceVariable 179784

version: 3; Last updated: 2023-12-01 22:26:01+0000

Profile: GroupAssignment

RelatesTo
type: cite-as
targetMarkdown:

GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis [EvidenceVariable]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179784. Revised 2023-11-30. Available at: https://fevir.net/resources/EvidenceVariable/179784. Computable resource at: https://fevir.net/resources/EvidenceVariable/179784.

url: https://fevir.net/resources/EvidenceVariable/179784

identifier: FEvIR Object Identifier/179784

name: Therapeutic_dose_anticoagulation_with_heparin_vs_Usual_care_pharmacologic_thromboprophylaxis

title: GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis in multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19